Department of Nutrition and Food Science, University of Ghana, Legon, Ghana.
Institute for Global Nutrition, Department of Nutrition, University of California, Davis, California, USA.
Matern Child Nutr. 2023 Jul;19(3):e13501. doi: 10.1111/mcn.13501. Epub 2023 Apr 6.
Little is known about the impact of small-quantity lipid-based nutrient supplements (SQ-LNSs) on maternal morbidity. This secondary outcome analysis aimed to compare morbidity symptoms among women in two trials evaluating the efficacy of SQ-LNSs. From enrolment (≤20-week gestation) to 6 months postpartum, Ghanaian (n = 1320) and Malawian (n = 1391) women were assigned to consume daily: 60 mg iron and 400 µg folic acid until childbirth and placebo thereafter (iron and folic acid [IFA] group); or multiple micronutrients (MMN); or 20 g/day SQ-LNSs. Within country, we used repeated measures logistic regression and analysis of variance models to compare group differences in the period prevalence and percentage of days of monitoring when women had fever, gastrointestinal, reproductive, and respiratory symptoms during the second and third trimesters of pregnancy (n ~ 1243 in Ghana, 1200 in Malawi) and 0-3 and 3-6 months postpartum (n ~ 1212 in Ghana, 730 in Malawi). Most outcomes did not differ significantly among groups, with the following exceptions: in Ghana, overall, the prevalence of vomiting was lower in the LNS (21.5%) than MMN (25.6%) group, with the IFA group (23.2%) in-between (p = 0.046); mean ± SD percentage of days with nausea was greater in the LNS (3.5 ± 10.3) and MMN (3.3 ± 10.4) groups than the IFA (2.7 ± 8.3) group (p = 0.002). In Malawi, during 3-6 month postpartum, the prevalence of severe diarrhoea was greater in the LNS (8.1%) than the MMN (2.9%) group, with IFA (4.6%) in-between, p = 0.041). We conclude that the type of nutrient supplement received during pregnancy and lactation generally does not influence morbidity symptoms in these settings. Clinicaltrials.gov identifiers: NCT00970866; NCT01239693.
关于小剂量脂类营养补充剂 (SQ-LNS) 对产妇发病率的影响知之甚少。本二次结局分析旨在比较两项评估 SQ-LNS 疗效的试验中女性的发病症状。从入组(≤20 孕周)至产后 6 个月,加纳(n=1320)和马拉维(n=1391)的女性被分配每天服用:60mg 铁和 400μg 叶酸,直至分娩,之后服用安慰剂(铁和叶酸 [IFA] 组);或多种微量营养素(MMN);或 20g/d SQ-LNS。在国内,我们使用重复测量逻辑回归和方差分析模型来比较第二和第三个孕期(加纳 n=1243,马拉维 n=1200)和产后 0-3 个月和 3-6 个月(加纳 n=1212,马拉维 n=730)期间当女性出现发热、胃肠道、生殖和呼吸道症状时,组间监测的发病率和天数百分比的差异。大多数结局在组间没有显著差异,以下情况除外:在加纳,总体而言,LNS(21.5%)组的呕吐发病率低于 MMN(25.6%)组,IFA 组(23.2%)处于两者之间(p=0.046);LNS(3.5±10.3)和 MMN(3.3±10.4)组的恶心天数的平均值+标准差大于 IFA 组(2.7±8.3)(p=0.002)。在马拉维,在产后 3-6 个月期间,LNS(8.1%)组严重腹泻的发病率高于 MMN(2.9%)组,IFA 组(4.6%)处于两者之间,p=0.041)。我们得出结论,在这些环境中,怀孕期间和哺乳期接受的营养补充剂类型通常不会影响发病症状。临床试验.gov 标识符:NCT00970866;NCT01239693。